组蛋白乙酰化、去乙酰化修饰是基因转录调控的关键机制之一,与肿瘤的发生、发展关系密切。乳腺癌是女性肿瘤中最常见的肿瘤之一,内分泌治疗是其主要治疗手段之一,但原发性和继发性内分泌治疗耐药极大地影响了治疗的效果,在体内外研究中证实组蛋白去乙酰化酶抑制剂(histone deacetylase inhibitors,HDACis)具有增敏内分泌治疗及逆转内分泌治疗耐药的作用,为提高内分泌治疗效果提供了新的选择。 Histone acetylation, deacetylation modification is one of the key mechanisms of gene transcription regulation, and tumor occurrence and development are closely related. Breast cancer is one of the most common tumors in female tumors. Endocrine therapy is one of the main treatment methods. However, the primary and secondary endocrine therapy resistance greatly affects the treatment effect. In vitro and in vivo studies confirmed that the group Histone deacetylase inhibitors (HDACis) have sensitizing endocrine therapy and reversing the role of endocrine therapy resistance, providing a new option for improving the effect of endocrine therapy.